الفهرس 
Introductionيوجد فقط 14 صفحة متاحة للعرض العام
 |  | from | 99 |  |  |
| | | from | 99 | | |
المستخلص
The current study aimed to evaluate the clinical and radiographic outcomes of Formocresol pulpotomy vs MTA-based zinc oxide eugenol pulpotomy in primary molars.
The split mouth technique was used on a total of 20 participants in this research. Each patient had two teeth, which were equally split into two groups according to the material used.
Which of the two groups the teeth were randomly assigned to depended on the substance used. Twenty teeth were repaired using a combination of formocresol zinc oxide eugenol and MTA-based zinc oxide eugenol.
After the pulpotomies, the coronal pulp was cut and restored using both materials.
The discomfort in the Formocresol group started on day one and disappeared by day seven, according to the study’s findings. MTA never showed any symptoms of distress. The difference between the two groups at 1 day was statistically significant (p=0.0001).
The current study revealed a significant difference between the two groups in terms of the clinical assessment at nine months (p = 0.0001). The MTA-based zinc oxide eugenol and Formocresol groups had success rates of 100% and 85%, respectively.
Based on radiographic inspection at the end of a year, the success rates for Formocresol and MTA-based zinc oxide eugenol were 85% and 65%, respectively.
Both groups were very different from one another.
According to the results of the experiment, despite Formocresol having been the gold standard in pulpotomy surgery for the last 20 years, 1-MTA-based zinc oxide eugenol was found to be a biocompatible drug with sealing and healing capabilities compared to FC.
2-Clinical and radiological results were better with MTA-based zinc oxide eugenol than with Formocresol.
3-The Formocresol group had post-operative pain.
4- Formocresol was associated with more radiographic failure than MTA-based zinc oxide eugenol.
5-MTA-based zinc oxide eugenol has a potential future as a Formocresol alternative in primary molars because to its biocompatibility, safety, simplicity of maintenance, capacity to reduce pulp inflammation, and cost-effectiveness.
6- To confirm the efficiency of MTA-based zinc oxide eugenol as a pulpotomy drug, more randomized clinical trials with histological analyses, a larger sample size, and longer follow-up periods are absolutely required.